| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US11529308 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(15 years from now) | |
Annovera is owned by Therapeuticsmd Inc.
Annovera contains Ethinyl Estradiol; Segesterone Acetate.
Annovera has a total of 7 drug patents out of which 0 drug patents have expired.
Annovera was authorised for market use on 10 August, 2018.
Annovera is available in ring;vaginal dosage forms.
Annovera can be used as method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles, method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception.
Drug patent challenges can be filed against Annovera from 2022-08-10.
The generics of Annovera are possible to be released after 21 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any su...
Dosage: RING;VAGINAL
ANNOVERA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic